XML 175 R48.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments under Research and Collaboration Agreements (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2022
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments           $ 11,100   $ 11,100  
Clinical development milestones.           14,000   14,000  
Regulatory events           80,000   80,000  
Commercial sales           150,000   150,000  
Milestone payments commercial milestones           12,000   12,000  
Extension royalties   $ 225           225  
Accrued extension royalties     $ 200     200   200 $ 200
Development milestones           32,500   32,500  
Annual sales milestone payments           $ 50,000   $ 50,000  
Net profits from licensed product sales           50.00%   50.00%  
Payment of development milestones       $ 3,300          
Accrued amount           $ 3,300   $ 3,300  
Patent costs reimbursements               0 49
Accrued liabilities     325     325   $ 325 379
Net sales of licensed products milestone payment               $3,995  
Other income           200 $ 3,556 $ 3,556
Research and Development Expense [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments           70,000   70,000  
Royalties amount     6   $ 6 19 $ 19 25 25
MedImmune License Agreement [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments           244,000   244,000  
NCI License Agreement [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments           3,995      
Royalties amount           25      
MSK License Agreement [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payment upon achieving           10,500   10,500  
Milestone payment on net sales           30,000   30,000  
Accrued royalties     790     790   790  
VAZYME License agreement [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments           200   200  
Accrued liabilities     $ 200     200   200 200
Other Accrued Expenses and Accounts Payable [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Patent costs reimbursements           273   273 273
Other Accrued Expenses [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Patent costs reimbursements           169   169 169
Accounts Payable [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Milestone payments                 790
Subsequent Event [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Payment of development milestones $ 3,300                
Minimum [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Royalties amount           20   20  
Minimum [Member] | Research and Development Expense [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Royalties amount               0 $ 20
Minimum [Member] | NCI License Agreement [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Royalties amount               25  
Maximum [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Royalties amount           $ 30   30  
Maximum [Member] | Research and Development Expense [Member]                  
Commitments under Research and Collaboration Agreements [Line Items]                  
Royalties amount               $ 498,000